CN101631798A - 产生非节段负链rna病毒的细胞和方法 - Google Patents

产生非节段负链rna病毒的细胞和方法 Download PDF

Info

Publication number
CN101631798A
CN101631798A CN200780047473A CN200780047473A CN101631798A CN 101631798 A CN101631798 A CN 101631798A CN 200780047473 A CN200780047473 A CN 200780047473A CN 200780047473 A CN200780047473 A CN 200780047473A CN 101631798 A CN101631798 A CN 101631798A
Authority
CN
China
Prior art keywords
leu
ala
cell
ser
ile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200780047473A
Other languages
English (en)
Chinese (zh)
Inventor
F·坦吉
P·沙尔诺
Y·雅各布
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut Pasteur
Original Assignee
Centre National de la Recherche Scientifique CNRS
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Institut Pasteur filed Critical Centre National de la Recherche Scientifique CNRS
Priority to CN201510019183.6A priority Critical patent/CN104745533A/zh
Publication of CN101631798A publication Critical patent/CN101631798A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN200780047473A 2006-12-22 2007-12-21 产生非节段负链rna病毒的细胞和方法 Pending CN101631798A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510019183.6A CN104745533A (zh) 2006-12-22 2007-12-21 产生非节段负链rna 病毒的细胞和方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06292025.1A EP1939214B1 (en) 2006-12-22 2006-12-22 Cells and methodology to generate non-segmented negative-strand RNA viruses
EP06292025.1 2006-12-22

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201510019183.6A Division CN104745533A (zh) 2006-12-22 2007-12-21 产生非节段负链rna 病毒的细胞和方法

Publications (1)

Publication Number Publication Date
CN101631798A true CN101631798A (zh) 2010-01-20

Family

ID=37831098

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200780047473A Pending CN101631798A (zh) 2006-12-22 2007-12-21 产生非节段负链rna病毒的细胞和方法
CN201510019183.6A Pending CN104745533A (zh) 2006-12-22 2007-12-21 产生非节段负链rna 病毒的细胞和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201510019183.6A Pending CN104745533A (zh) 2006-12-22 2007-12-21 产生非节段负链rna 病毒的细胞和方法

Country Status (11)

Country Link
US (2) US8586364B2 (enExample)
EP (2) EP1939214B1 (enExample)
JP (2) JP5902371B2 (enExample)
KR (1) KR101469007B1 (enExample)
CN (2) CN101631798A (enExample)
BR (1) BRPI0719469C1 (enExample)
CA (1) CA2673262C (enExample)
DK (2) DK1939214T3 (enExample)
ES (2) ES2423518T3 (enExample)
MX (1) MX2009006755A (enExample)
WO (1) WO2008078198A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103906843A (zh) * 2011-06-08 2014-07-02 维什瓦斯·乔希 双质粒哺乳动物表达系统
CN109355301A (zh) * 2018-08-22 2019-02-19 深圳大学 一种石斑鱼重组NNVcp的密码子优化的核酸序列、融合表达载体、制备方法及其本身
WO2019061691A1 (zh) * 2017-09-26 2019-04-04 王红伟 一种可诱导性拯救弹状病毒的细胞系及其构建方法与应用

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1375670B1 (en) 2002-06-20 2013-06-12 Institut Pasteur Recombinant measles viruses expressing epitopes of antigens of RNA viruses and use of the recombinant viruses for the preparation of vaccine compositions
ES2330309T3 (es) 2002-06-20 2009-12-09 Institut Pasteur Adnc infeccioso de una cepa de vacuna aprobada de virus del sarampion. uso para composiciones inmunogenicas.
CA2432738A1 (en) 2003-02-26 2004-08-26 Philippe Despres New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
WO2012038832A2 (en) * 2010-09-24 2012-03-29 Institut Pasteur Generation of replicating chimeric measles virus - retrovirus particles
FR2994697B1 (fr) * 2012-08-24 2016-05-13 Centre De Coop Int En Rech Agronomique Pour Le Dev (Cirad) Souche vaccinale marquee du virus de la peste des petits ruminants, et son procede d'obtention
EP2712871A1 (en) 2012-09-27 2014-04-02 Institut Pasteur Recombinant Measles virus expressing Chikungunya virus polypeptides and their applications
EP2759301A1 (en) 2013-01-24 2014-07-30 Institut Pasteur Use of a genetically modified infectious measles virus with enhanced pro-apoptotic properties (MV-DeltaC virus)
US20140255447A1 (en) * 2013-03-05 2014-09-11 Biomune Company Production of avian embryo cells
WO2015092710A1 (en) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Contralateral co-administration of vaccines
US11535864B2 (en) 2015-01-05 2022-12-27 Vishwas Dattatraya JOSHI DNA molecules producing custom designed replicating and non-replicating negative stranded RNA viruses and uses there of
EP3184119A1 (en) 2015-12-23 2017-06-28 Themis Bioscience GmbH Chromatography based purification strategies for measles scaffold based viruses
EP3255056A1 (en) * 2016-06-06 2017-12-13 Commissariat À L'Énergie Atomique Et Aux Énergies Alternatives Method for producing self-assemblying paramyxoviral nucleocapsid-like particles and their uses
US11351246B2 (en) 2017-05-09 2022-06-07 Invectys SAS Recombinant measles vaccine expressing hTERT
EP3412307A1 (en) 2017-06-07 2018-12-12 Institut Pasteur Recombinant measles virus expressing zika virus proteins and their applications
JP7225254B2 (ja) 2017-11-09 2023-02-20 アンスティテュ・パストゥール 非構造タンパク質を含むジカウイルスキメラポリエピトープ、及び免疫原性組成物におけるその使用
CA3085224A1 (en) 2017-12-21 2019-06-27 Institut Pasteur Measles-vectored lassa vaccine
WO2020012037A1 (en) * 2018-07-13 2020-01-16 Valneva Se Method for rescuing and producing a virus in avian cells
CN111218474A (zh) * 2018-11-23 2020-06-02 成都生物制品研究所有限责任公司 一种副粘病毒的拯救系统和副粘病毒拯救方法
EP3673917A1 (en) 2018-12-28 2020-07-01 Themis Bioscience GmbH Norovirus vaccines
CN109913423A (zh) * 2019-03-27 2019-06-21 扬州大学 一种稳定表达猪德尔塔冠状病毒N蛋白的重组Vero细胞系及应用
EP3865180A1 (en) 2020-02-13 2021-08-18 Institut Pasteur Live recombinant measles virus expressing coronavirus antigens - its use in eliciting immunity against coronaviruses
JP2023513913A (ja) 2020-02-13 2023-04-04 アンスティテュ・パストゥール 麻疹ベクターを用いたｃｏｖｉｄ－１９免疫原性組成物及びワクチン
US20230310581A1 (en) * 2020-04-27 2023-10-05 Ohio State Innovation Foundation A live attenuated measles virus vectored vaccine for sars-cov-2
EP3936517A1 (en) * 2020-07-08 2022-01-12 Institut Pasteur An improved measles virus vaccine vector based on multiple tandem additional transcription units
CA3204201A1 (en) 2021-01-13 2022-07-21 Thierry Heidmann Measles-hiv or measles-htlv vaccine
US20250304921A1 (en) * 2022-05-27 2025-10-02 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Reverse genetics system for feline morbillivirus
EP4501946A1 (en) 2023-07-31 2025-02-05 LoopLab Bio GmbH Self-amplifying biologics for targeted therapy
CN120648655A (zh) * 2025-08-21 2025-09-16 内蒙古自治区农牧业科学院 一株t7-293t细胞及其在牛副流感病毒3型感染性克隆拯救病毒中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997006270A1 (en) * 1995-08-09 1997-02-20 Schweiz. Serum- & Impfinstitut Bern cDNA CORRESPONDING TO THE ANTIGENOME OF NONSEGMENTED NEGATIVE STRAND RNA VIRUSES, AND PROCESS FOR THE PRODUCTION OF SUCH VIRUSES ENCODING ADDITIONAL ANTIGENICALLY ACTIVE PROTEINS

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1050210B (en) 1999-10-12 2007-08-24 Institut Pasteur Lentiviral triplex dna, and vectors and recombinant cells containing lentiviral triplex dna
JP2004503233A (ja) 2000-06-16 2004-02-05 インスティティ・パスツール デング熱ウイルスエンベロープ糖タンパク質のプロ−アポトーシスフラグメント
EP1375670B1 (en) 2002-06-20 2013-06-12 Institut Pasteur Recombinant measles viruses expressing epitopes of antigens of RNA viruses and use of the recombinant viruses for the preparation of vaccine compositions
DE10234579A1 (de) * 2002-07-30 2004-02-12 Zf Friedrichshafen Ag Getriebe
KR100999316B1 (ko) * 2003-06-09 2010-12-10 와이어쓰 엘엘씨 ｃＤＮＡ로부터의 비분절 네가티브 쇄 ＲＮＡ 바이러스의회수를 위한 개선된 방법
CA2549188A1 (fr) 2003-12-02 2005-06-23 Universite Paris 7 Utilisation des proteines et des peptides codes par le genome d'une nouvelle souche de coronavirus associe au sras
FR2870126B1 (fr) 2004-05-17 2009-07-17 Pasteur Institut Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
CN101198353A (zh) * 2005-04-14 2008-06-11 昆士兰大学 免疫调节组合物和其应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997006270A1 (en) * 1995-08-09 1997-02-20 Schweiz. Serum- & Impfinstitut Bern cDNA CORRESPONDING TO THE ANTIGENOME OF NONSEGMENTED NEGATIVE STRAND RNA VIRUSES, AND PROCESS FOR THE PRODUCTION OF SUCH VIRUSES ENCODING ADDITIONAL ANTIGENICALLY ACTIVE PROTEINS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AUDE SIRCEN等: "Enhanced Transgene Expression in Cord Blood CD34+-Derived Hematopoietic Cells， Including Developing T Cells and NOD/SCID Mouse Repopulating Cells，Following Transduction with Modified TRIP Lentiviral Vectors", 《MOLECULAR THERAPY》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103906843A (zh) * 2011-06-08 2014-07-02 维什瓦斯·乔希 双质粒哺乳动物表达系统
CN103906843B (zh) * 2011-06-08 2016-12-07 维什瓦斯·乔希 双质粒哺乳动物表达系统
WO2019061691A1 (zh) * 2017-09-26 2019-04-04 王红伟 一种可诱导性拯救弹状病毒的细胞系及其构建方法与应用
CN109355301A (zh) * 2018-08-22 2019-02-19 深圳大学 一种石斑鱼重组NNVcp的密码子优化的核酸序列、融合表达载体、制备方法及其本身

Also Published As

Publication number Publication date
ES2686168T3 (es) 2018-10-16
CA2673262A1 (en) 2008-07-03
KR101469007B1 (ko) 2014-12-05
BRPI0719469B1 (pt) 2019-07-02
EP2091962A2 (en) 2009-08-26
ES2423518T3 (es) 2013-09-20
KR20090103922A (ko) 2009-10-01
US8586364B2 (en) 2013-11-19
US20140051148A1 (en) 2014-02-20
JP5902371B2 (ja) 2016-04-13
BRPI0719469A2 (pt) 2014-02-11
DK2091962T3 (en) 2018-10-08
JP2015015955A (ja) 2015-01-29
JP2010512779A (ja) 2010-04-30
US20100144040A1 (en) 2010-06-10
DK1939214T3 (da) 2013-10-14
EP1939214B1 (en) 2013-07-10
WO2008078198A3 (en) 2008-10-30
US9499799B2 (en) 2016-11-22
WO2008078198A2 (en) 2008-07-03
EP1939214A1 (en) 2008-07-02
MX2009006755A (es) 2009-07-31
EP2091962B1 (en) 2018-07-04
CN104745533A (zh) 2015-07-01
BRPI0719469C1 (pt) 2021-05-25
CA2673262C (en) 2019-03-05

Similar Documents

Publication Publication Date Title
KR101469007B1 (ko) 비분절 음성 가닥 ｒｎａ 바이러스 생성하는 세포 및 방법
US20230364266A1 (en) Methods and compositions for genomic integration
DK2900687T3 (en) RECOMBINANT MEASUREMENT VIRUS FOR EXPRESSING CHIKUNGUNYA VIRUS POLYPEPTIDES AND THEIR USE
KR101120784B1 (ko) 파라믹소바이러스용 백신으로서의 바이러스-유사 입자
KR101241423B1 (ko) 알엔에이 바이러스 항원의 에피토프를 발현하는 재조합홍역 바이러스-백신 제제의 제조에 사용하기 위한 용도
ES2663224T3 (es) ADNc infeccioso de una cepa de vacuna aprobada del virus del sarampión. Uso para composiciones inmunogénicas
KR20100092041A (ko) ｃＤＮＡ로부터의 비분절 네가티브 쇄 ＲＮＡ 바이러스의 회수를 위한 개선된 방법
AU2018254529B2 (en) Therapeutic genome editing in Wiskott-Aldrich syndrome and X-linked thrombocytopenia
JP7311872B2 (ja) キメラｒｓｖ、免疫原性組成物、及び使用方法
CN110214182A (zh) 用于i型黏多糖贮积症的基因治疗
EP3923983A1 (en) Chimeric rsv and hmpv f proteins, immunogenic compositions, and methods of use
CN101868249B (zh) 治疗间皮瘤的药物和方法
US6475780B1 (en) Alphavirus vectors for paramyxovirus vaccines
CN112852871A (zh) 高效编辑家蚕基因组的Cas9系统及其应用
AU2021327911B2 (en) Nucleic acid construct for increasing adeno-associated virus yield, and construction method therefor
KR20230150998A (ko) Cas3 단백질을 제조하는 방법
CN113667017A (zh) 一种可提高CRISPR/Cas9系统同源重组效率的方法和应用
CN114606174A (zh) 一种生物合成原儿茶酸甲酯的菌株及应用
CN115197949A (zh) 一种重组新城疫病毒rNDV-OX40L、其基因组、制备方法及其用途
HK40024932A (en) Therapeutic agent comprising nucleic acid and car-modified immune cell and application thereof
HK40024481A (en) Therapeutic genome editing in wiskott-aldrich syndrome and x-linked thrombocytopenia

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20100120